Ignite Creation Date:
2024-05-06 @ 1:27 PM
Last Modification Date:
2024-10-26 @ 1:14 PM
Study NCT ID:
NCT04027712
Status:
UNKNOWN
Last Update Posted:
2019-07-23
First Post:
2019-07-18
Brief Title:
Platelet Reactivity B-amyloid MOTS-c and Mortality of Type II Diabetics With CAD
Sponsor:
University of Athens
Organization:
University of Athens
Study Overview
Official Title:
High On-treatment Platelet Reactivity Increased B-amyloid and Downregulation of MOTS-c Predict Mortality in Patients With Coronary Artery Disease and Type 2 Diabetes Mellitus a 2-year Follow up Study
Status:
UNKNOWN
Status Verified Date:
2019-07
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Increased circulating b-amyloid and decreased Mitochondrial-derived peptide MOTS-c a peptide improving tissue insulin sensitivity are reported in diabetes The investigators plan to investigate the association of both biofactors with high on-clopidogrel platelet reactivity and cardiovascular mortality in type 2 diabetic patients with Coronary artery disease
Detailed Description:
In type II diabetic patients with Coronary artery disease treated with clopidogrel and aspirin the investigators plan to measure i maximum platelet aggregation to adenosine diphosphate ADP by Light Transmission Aggregometry LTAmax as a marker of on-clopidogrel treatment platelet reactivity ii Malondialdehyde MDA as oxidative stress marker Mitochondrial-derived peptide MOTS-c and b-amyloid blood levels
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None